NervGen Pharma Corp. (NGEN.V)
| Previous Close | 1.7600 |
| Open | 1.8000 |
| Bid | 1.7400 x 0 |
| Ask | 1.7500 x 0 |
| Day's Range | 1.7500 - 1.8600 |
| 52 Week Range | 1.2100 - 2.6500 |
| Volume | 17,034 |
| Avg. Volume | 41,837 |
| Market Cap | 68.444M |
| Beta (5Y Monthly) | 2.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3440 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - July 16, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced that the Company has granted 125,000 incentive stock options to existing consultants providing investor relations services, 25,000 of which are exercisable at a price of $1.75 per share and 100,000 of which are exercisabl
- Newsfile
NervGen Pharma Establishes Multiple Sclerosis Clinical Advisory Board
NervGen Supports World Brain Day on July 22 to "Stop Multiple Sclerosis" Vancouver, British Columbia--(Newsfile Corp. - July 15, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced the formation of its Multiple Sclerosis (MS) Clinical Advisory Board comprised of six world-class scientific and clinical researchers in the field o
- Newsfile
NervGen Pharma Expands Alzheimer's Disease Scientific Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - July 12, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced the addition of three world-class scientists and clinical researchers to its Alzheimer's Disease Scientific Advisory Board. Drs. Martin Farlow, Reisa Sperling and Michael Weiner have agreed to join Drs. Jeffrey Cummings,
